Alpenglow Biosciences and Virdx Announce Strategic Deal to Advance AI-Enabled Prostate Cancer Diagnostics
Why this partnership matters: Artificial intelligence (AI) diagnostics thrive on one thing: rock-solid data. Alpenglow Biosciences has entered a multi-year, milestone-based agreement with Virdx, a biophysics AI company focused on MRI-based cancer detection, to supply exactly that: whole-tissue 3D light-sheet microscopy (LSM) datasets capturing architectural context, cellular detail, and rare features not visible with current clinical imaging modalities. The project aims to enhance MRI-based predictions using high-resolution 3D microscope images.
Inside the collaboration
Scope: Build a comprehensive 3D LSM dataset from human prostate tissue, serving as high-resolution ground truth to assess and enhance the performance of Virdx’s MRI-based prostate cancer diagnostics effort.
Tech stack: Using NVIDIA GPUs on local infrastructure, Alpenglow Biosciences and Virdx process extensive 3D microscopy datasets, each measuring several terabytes. This NVIDIA GPU-enabled pipeline is >10x faster than existing CPU-based pipelines, which enables Alpenglow and Virdx to partner on a large-scale clinical trial. Alpenglow Biosciences is a member of NVIDIA Inception, a global program for cutting-edge startups.
“High‑quality 3D data is the launchpad for the next wave of AI diagnostic tools”
What this means for patients & partners: Earlier, more accurate detection of clinically significant prostate cancer, reducing unnecessary interventions.
The road ahead.
This agreement demonstrates the value of exceptional ground truth data for AI-based clinical tools and highlights the expanding role of 3D pathology in bridging radiology and pathology with non-destructive, volumetric imaging.
